Veradermics, Incorporated has announced the completion of participant enrollment for its second Phase 3 clinical trial of VDPHL01, a new oral medication designed to treat male pattern hair loss. The study, which involved about 1,000 male participants across all company trials, marks a major step forward in the company’s efforts to address hair loss with innovative therapies. The company’s stock price has also shown strength, indicating optimism among investors as clinical testing progresses.
VDPHL01 is a once or twice-daily oral treatment that uses extended-release minoxidil to help people with pattern hair loss. Unlike current therapies, which often rely on hormones or topical solutions, VDPHL01 is being positioned as the first non-hormonal oral treatment of its type that could earn approval from the U.S. Food and Drug Administration. Pattern hair loss is a condition that affects an estimated 50 million men and 30 million women across the United States, highlighting the urgent need for new treatment options.
The recently completed Phase 3 trial known as ‘304’ enrolled 536 men who have mild-to-moderate symptoms of hair loss. The study is testing two dosage methods—one taken once daily and the other twice daily—over the span of a year. Researchers are primarily looking for increases in hair count that are not vellus (fine body hair) and are also tracking changes reported by patients in their own hair coverage after 24 weeks of treatment.
Reid Waldman, Chief Executive Officer of Veradermics, called the completion of the male-phase trials a “significant milestone” for both the company and the development of VDPHL01. In addition to trials involving male participants, the company is now working to enroll female participants in a separate Phase 2/3 study, aiming to broaden the medication’s potential impact.
If approved by regulators, VDPHL01 would be the first new, prescription medicine for pattern hair loss approved in the United States in nearly thirty years. The extended-release technology used in the medication is designed to maintain steady minoxidil levels in the bloodstream, which may allow for better hair growth while reducing the risk of cardiac side effects that can occur with higher concentration peaks. The company holds patents for VDPHL01 that are valid through 2043, supporting its long-term research and potential market presence.
